- Home
- PEPG vs CLLS Comparison
PEPG vs CLLS Comparison
Compare PEPG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- CLLS
- Stock Information
- Founded
- PEPG 2018
- CLLS 1999
- Country
- PEPG United States
- CLLS France
- Employees
- PEPG N/A
- CLLS N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- CLLS Health Care
- Exchange
- PEPG Nasdaq
- CLLS Nasdaq
- Market Cap
- PEPG 317.6M
- CLLS 299.0M
- IPO Year
- PEPG 2022
- CLLS 2007
- Fundamental
- Price
- PEPG $4.91
- CLLS $3.78
- Analyst Decision
- PEPG Strong Buy
- CLLS Buy
- Analyst Count
- PEPG 6
- CLLS 1
- Target Price
- PEPG $9.17
- CLLS $8.00
- AVG Volume (30 Days)
- PEPG 676.6K
- CLLS 135.2K
- Earning Date
- PEPG 11-06-2025
- CLLS 11-07-2025
- Dividend Yield
- PEPG N/A
- CLLS N/A
- EPS Growth
- PEPG N/A
- CLLS N/A
- EPS
- PEPG N/A
- CLLS N/A
- Revenue
- PEPG N/A
- CLLS $82,551,000.00
- Revenue This Year
- PEPG N/A
- CLLS N/A
- Revenue Next Year
- PEPG N/A
- CLLS $58.00
- P/E Ratio
- PEPG N/A
- CLLS N/A
- Revenue Growth
- PEPG N/A
- CLLS 129.04
- 52 Week Low
- PEPG $0.88
- CLLS $1.10
- 52 Week High
- PEPG $6.85
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- PEPG 56.79
- CLLS 57.42
- Support Level
- PEPG $4.05
- CLLS $3.12
- Resistance Level
- PEPG $4.89
- CLLS $3.79
- Average True Range (ATR)
- PEPG 0.40
- CLLS 0.19
- MACD
- PEPG -0.07
- CLLS 0.01
- Stochastic Oscillator
- PEPG 51.90
- CLLS 90.54
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.